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Insulin-like peptide 3 (INSL3), a member of the relaxin pep-
tide family, is produced in testicular Leydig cells and ovarian
thecal cells. Gene knock-out experiments have identified a key
biological role in initiating testes descent during fetal develop-
ment. Additionally, INSL3 has an important function in medi-
atingmale and female germ cell function. These actions are elic-
ited via its recently identified receptor, LGR8, a member of the
leucine-rich repeat-containing G-protein-coupled receptor
family. To identify the structural features that are responsible
for the interaction of INSL3 with its receptor, its solution struc-
ture was determined by NMR spectroscopy together with in
vitro assays of a series of B-chain alanine-substituted analogs.
Synthetic human INSL3 was found to adopt a characteristic
relaxin/insulin-like fold in solution but is a highly dynamicmol-
ecule. The four termini of this two-chain peptide are disordered,
andadditional conformational exchange is evident in themolec-
ular core. Alanine-substituted analogs were used to identify the
key residues of INSL3 that are responsible for the interaction
with the ectodomain of LGR8. These include ArgB16 and ValB19,
withHisB12 andArgB20 playing a secondary role, as evident from
the synergistic effect on the activity in double and triplemutants
involving these residues. Together, these amino acids combine
with the previously identified critical residue, TrpB27, to form
the receptor binding surface. The current results provide clear
direction for the design of novel specific agonists and antago-
nists of this receptor.
Insulin-like peptide 3 (INSL34; also knownas relaxin-like fac-
tor and Leydig cell insulin-like peptide) was originally discov-
ered and isolated as a cDNA clone from a boar testis cDNA
library (1). It is primarily produced by prenatal and postnatal
mature Leydig cells of the testis and the thecal cells of the ovary.
Its primary structure showed it to be a bona fidemember of the
insulin-insulin-like growth factor-relaxin superfamily, which is
now known to have a total of ten members in the human. Like
insulin, INSL3 is firstly synthesized as a pre-prohormone pre-
cursor containing a signal peptide linked to B-C-A domains. It
undergoes processing by hitherto unidentified proprotein con-
vertases, resulting in the production of mature INSL3 consist-
ing of a A-B heterodimer that is covalently linked by two inter-
chain disulfide bonds and one intrachain disulfide bond (Fig. 1)
(2). These disulfide bonds are essential for maintaining its
expected characteristic insulin-like conformation and its
unique biological activities (3). The receptor for INSL3, LGR8,
is a member of the leucine-rich repeat-containing G-protein-
coupled receptor family (4). It is closely related to the relaxin
receptor, LGR7, and has been recently classified as relaxin fam-
ily peptide (RXFP) receptor, RXFP2 (5). Importantly, relaxin
peptides from some species can also bind to and activate LGR8,
albeit with a lower affinity than INSL3 (5).
Male mice homozygous with targeted disruption of either
the Insl3 or LGR8 gene exhibit bilateral cryptorchidism (6, 7), a
defect in testicular descent due to an abnormality in gubernacu-
lar development. In humans this is the most common congen-
ital disorder during sexual differentiation, affecting 3–5% of
newborn male infants (8). It results in defective spermatogene-
sis, infertility, and an associated high risk for testicular malig-
nancy. Female homozygous mice show impaired fertility asso-
ciated with abnormal estrus cycle length (6). Overexpression of
the INSL3 protein in female mice causes the ovaries to descend
into the inguinal region due to an overdeveloped gubernaculum
(9). Synthetic INSL3 will induce the growth of the gubernacu-
lum in whole organ cultures (10). Hence the peptide is essential
for the transabdominal phase of testicular descent where the
gubernaculum proliferates and results in the migration of the
testis to the inguinal region. More recent studies have uncov-
ered prominent new roles for INSL3 in modulating both male
and female germ cell function (11). In mammals it is well rec-
ognized that germ cell maturation is controlled by luteinizing
hormone (LH). Oocyte maturation is induced by the pre-ovu-
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latory surge of LH, and, in the testis, the survival of male germ
cells is also controlled by LH. However, because LH acts on the
follicular cells in the female and the Leydig cells of themale, and
not on the germ cells directly, local paracrine factors are likely
involved in direct regulation of germ cellmaturation. It has now
been demonstrated that LH acts on the ovarian theca and tes-
ticular Leydig cells to produce INSL3 (11). This INSL3 can then
bind to the LGR8 receptor, which is present on the germ cells to
activate the inhibitory G-protein (Gi) leading to decreased
cAMP production. Hence, treatment with INSL3 initiatedmei-
otic progression (as measured by germinal vesicle breakdown)
in arrested oocytes in vitro and reversed the decrease in testis
weight (caused by increased germ cell apoptosis), which is
induced by a gonadotrophin-releasing hormone antagonist in
vivo (11). This significant finding demonstrates that INSL3 has
a potential clinical application as a highly specific regulator of
fertility. Furthermore, LGR8 antagonists have the potential to
be highly specific contraceptives. Indeed, we recently demon-
strated that LGR8 antagonists based on cyclic peptidemimetics
of the INSL3 B-chain can mimic the effect of gonadotrophin-
releasing hormone antagonist treatment in prepubertal rats,
suggesting that direct antagonism of LGR8 function may be an
effective contraceptive treatment (12).
The results of recent structure-function studies of INSL3
have shown that the primary receptor binding region resides
within its B-chain. Analogs of INSL3 with modifications in the
B-chain at positions 25 and 27 have shown that Trp27 is essen-
tial for characteristic INSL3 activity (13). More recently, our
demonstration, that B-chain-only INSL3 peptides can bind to
the primary ligand binding site in the ectodomain of LGR8 and
act as antagonists (12), has highlighted that the B-chain con-
tains the essential residues for primary binding. It has also
enabled a detailed structure-activity relationship study of ana-
logs of the linear peptide to be undertaken. The results showed
that the minimum length required for binding was residues
11–27 and confirmed the critical importance of the Trp27 res-
idue (12). On the basis of this information and tomore precisely
map the primary LGR8 receptor binding domain of human
INSL3, we undertook its solution structure determination and
correlated this with the LGR8 binding activation of INSL3 ana-
logs with selected alanine substitutions in the B-chain.
EXPERIMENTAL PROCEDURES
Solid-phase Peptide Synthesis—Human INSL3 and its ana-
logs were synthesized using continuous flow Fmoc (N-(9-flu-
orenyl)methoxycarbonyl)-solid phase methodology together
with regioselective disulfide bond formation as previously
described (14). Following sequential
formation of the three disulfide
bonds by oxidation, thiolysis, and
iodolysis, respectively, the crude
peptides were purified by reversed-
phase high-performance liquid
chromatography using a gradient of
CH3CN in 0.1% aqueous trifluoro-
acetic acid. The eight B-chain Ala-
substituted INSL3 analogs thatwere
prepared were: B12(His 3 Ala),
B13(His3 Ala), B16(Arg3 Ala), B19(Val3 Ala), B20(Arg3
Ala), B12,16, B16,20, B12,16,20, and B12,16,19,20,27. Addition-
ally, an INSL3 analog was prepared in which the B-chain was
truncated by five residues from the C terminus; i.e. B1–26.
Peptide Characterization—The purity of each synthetic pep-
tide was assessed by analytical reversed-phase high-perform-
ance liquid chromatography andMALDI-TOFmass spectrom-
etry using a Bruker Autoflex II instrument (Bremen, Germany)
in the linear mode at 19.5 kV. Peptides were quantitated by
amino acid analysis of a 24-h acid hydrolyzate using a GBC Ltd.
analyzer (Melbourne, Australia).
Ligand Binding Assays—The method to study the binding of
125I-INSL3 to HEK-293T cells stably transfected with human
LGR8 has been described previously (15). 125I-INSL3 was
kindly provided by Prof. Pierre DeMeyts (Hegedorn Research
Institute, Denmark). Data are expressed as mean S.E. of per-
cent specific binding of triplicate determinations made from at
least three independent experiments. Data were analyzed using
GraphPad Prism (GraphPad Inc., San Diego, CA), and a non-
linear regression one-site binding model was used to plot
curves and calculate pKi values. Final pooled pKi data were ana-
lyzed using one-way analysis of variance coupled with Bonfer-
roni’s multiple comparison test formultiple group comparison.
Functional cAMP Assays—Receptor cAMP signaling was
assessed using a cAMP reporter gene assay (16). 293T cells in
96-well plates were co-transfected with LGR8 and a pCRE--
galactosidase reporter plasmid (16) (courtesy of Dr. R. Cone) to
assess the cAMP signaling response to INSL3 and INSL3 ana-
logs. Co-transfected cells were incubated with increasing con-
centrations of INSL3 analogs for 6 h, after which the medium
was aspirated and the cells were frozen at 80 °C overnight.
The amount of cAMP-driven -galactosidase expression in
eachwell was determined by incubating the cells in 25l of lysis
buffer (10 mM sodium phosphate buffer, pH 8.0, 0.2 mM
MgSO4, 0.01mMMnCl2) for 10min, 100l of assay buffer (100
mM sodium phosphate buffer, pH 8.0, 2 mM MgSO4, 0.1 mM
MnCl2, 0.5% Triton X-100, 40 mM -mercaptoethanol) for a
further 10 min before 25 l of enzyme substrate solution (1
mg/ml chlorophenol red -D galactopyranoside (Roche
Applied Science) in 100mM sodiumphosphate buffer, pH 8.0, 2
mM MgSO4, 0.1 mM MnCl2) was added to each well, and the
plate was incubated for 30 min. The absorbance of each well
was determined at 570 nm using a Ceres UV900C plate reader
(Bio-Tek Instruments). All experiments were repeated at least
three times with triplicate determinations within each assay.
Results are plotted as mean  S.E. of percent normalized
response compared with 1 nM INSL3. Data were analyzed using
FIGURE 1. Primary structure and amino acid residue numbering of human INSL3. B-chain residues that
were substituted individually or in groups with alanine are shown in bold.
Solution Structure of INSL3
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one-way analysis of variance coupled with Bonferroni’s multi-
ple comparison test for multiple group comparison.
NMR Spectroscopy—Pulsed-field gradient NMR diffusion
experiments were performedwith a two-dimensional sequence
using stimulated echo longitudinal encode-decode (17) as
described previously (18). Dioxane (0.2 mM) was used as the
internal standard (19). Samples prepared for structure determi-
nation contained 1 mM of peptide dissolved in either 90%
H2O and 10% D2O (v/v) or 100% (v/v) D2O at pH 4.0. Spectra
were recorded at 290, 298, and 303 K on a Bruker Avance 600-
MHz spectrometer or on a Bruker DMX 750-MHz spectrome-
ter. Two-dimensional experiments recorded included double
quantum filtered correlation spectroscopy (DQF-COSY),
TOCSY (using an MLEV-17 spin lock sequence with a mixing
time of 80 ms), and NOESY with mixing times of 100, 150, or
200 ms. Slowly exchanging NH protons were detected by
acquiring a series of one-dimensional and TOCSY spectra
immediately after dissolution in D2O. As most amides disap-
peared within the first 1 h, resonances still visible after 1 h were
considered to be protected from the solvent by hydrogen bond-
ing. These included LeuA12, SerA13, CysA15, LeuA20, LeuA21,
ThrA22, LeuA23, CysA24, GluB7, LeuB9, ArgB16, AlaB17, LeuB18,
ValB19, ArgB20, ValB21, and CysB24. Spectra were processed
using XWINNMR (Bruker).
Structure Calculations—Distance restraints were derived
primarily from 150-ms NOESY spectra recorded at 298 K and
600 MHz in H2O or D2O. Cross-peaks were assigned and inte-
grated in XEASY and converted to distance restraints using
CYANA. Due to the generally broad lines of many amide pro-
tons, the 3JNH-H coupling constants were ambiguous. Thus, in
most cases, broad  angle restraints of 100  80° were
included, and then only for residues where a positive  angle
could be excluded based on a strong sequential Hi1-HNi
NOE compared with the intra residual Hi-HNi NOE. Side-
chain 1 angles and stereospecific assignments were deter-
mined on the basis of observed NOE and 3JH-H coupling pat-
terns. Hydrogen bonds were included into the structure
calculations for all amide protons concluded to be slow
exchanging once a suitable acceptor could be identified in the
preliminary structures. Three-dimensional structureswere cal-
culated using simulated annealing and energy minimization
protocols fromARIA (20) in the programCNS (21) as described
previously (18). Briefly the protocol involves a high tempera-
ture phase comprising 4000 steps of 0.015 ps of torsion angle
dynamics, a cooling phase with 4000 steps of 0.015 ps of torsion
angle dynamics duringwhich the temperature is lowered to 0K,
and finally an energy minimization phase comprising 5000
steps of Powell minimization. The subsequent refinement in
explicit water involves heating to 500 K via steps of 100 K, each
comprising 50 steps of 0.005 ps of Cartesian dynamics followed
by 2500 steps of 0.005 ps of Cartesian dynamics at 500 K, before
a cooling phase where the temperature is lowered in steps of
100 K, each comprising 2500 steps of 0.005 ps of Cartesian
dynamics. Finally, the structures were minimized with 2000
steps of Powellminimization. The coordinates representing the
solution structure of INSL3 have been submitted to the Protein
Data Bank and given the accession number 2H8B.
RESULTS
Synthesis of Human INSL3 and Analogs—Human INSL3 has
previously been successfully prepared in our laboratories by
random combination of each of the A- and B-chains at high pH
(22). Although overall yields were good, equivalent yields but
with an easier scale-up were obtained by a regioselective disul-
fide bond formation approach. The nine B-chain Ala-substi-
tuted INSL3 analogswere alsomade by the samemethod and in
good yield. Each peptidewas comprehensively chemically char-
acterized including by MALDI-TOF mass spectrometry (see
supplementary material) and its high purity confirmed.
NMR Diffusion Measurements—Translational diffusion meas-
urements using pulsed-field gradient experiments with dioxane
(hydrodynamic radius 2.12Å) as an internal standardwere used
to assess the aggregation state of INSL3 in solution.On the basis
of the equation derived by Wilkins et al. (19) (Rh  (4.75 
1.11)N0.290.02, where N is the number of residues in the pro-
tein and Rh is the hydrodynamic radius in Angstroms) the
expected hydrodynamic radii for a monomer (57 amino acids)
and a dimer (114 amino acids) of INSL3 are 15.3 and 18.8 Å,
respectively. The experimental hydrodynamic radius of INSL3
was found to be 16.7 Å at both 0.1 and 1 mM, confirming that
there is no concentration-dependent aggregation. Although
this value is a little higher than expected for a monomer,
given the identical diffusion coefficients at the two concentra-
tions this likely reflects a less compact structure rather than any
aggregation.
NMR Assignments and Structure Determination of INSL3—
For the structure determination of INSL3, extensive two-di-
mensional NMR data were recorded at 600 and 750 MHz.
Although the signals were well dispersed indicative of a folded
structure a large number of residues had significantly broad-
ened resonances. Despite this broadening it was possible to
achieve resonance assignments using two-dimensional sequen-
tial assignment strategies. For the amide protons of residues
AlaA7, ArgA8, CysA11, SerA13, GlyA14, and PheB14, the broaden-
ing of the amide signals was so severe that they could not be
detected. However, the side-chain resonances from these resi-
dues were assigned based on their patterns in the aliphatic
region of the TOCSY spectrum, and the assignments were con-
firmed by sequential as well asmedium and long rangeNOEs. A
number of other residues had broadened signals, including
CysA10, CysA15, ThrA16, GluB7, LysB8, LeuB9, CysB10, GlyB11, and
HisB12, confirming that INSL3 undergoes considerable confor-
mational exchange in solution. Furthermore, minor conforma-
tions appeared to be present for several residues, as evident
from “brothering” of signals. This is in agreementwithwhat has
previously been seen for H3 relaxin in solution, confirming that
peptides of the relaxin family are quite flexible. To assess
whether the structure or dynamic processes in INSL3 were
affected by solution conditions, spectra were recorded in the
pH range 2.7–7.4 (supplementary data). Although in general
resonance broadening was increased at higher pH as a result of
faster solvent exchange, no significant changes in H chemical
shifts or changes in the prevalence of minor conformations
were observed as a function of pH. INSL3 contains five Pro
residues of which one is the N-terminal residue of the B-chain.
Solution Structure of INSL3
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The other four are all in the trans conformation, as evident
from strong sequential Hi1-Hi NOEs, respectively.
Structural restraints in the form of distance restraints based
on NOE cross-peak intensities, backbone and side-chain dihe-
dral angle restraints derived from coupling constants and NOE
patterns, and hydrogen bonds derived from amide-exchange
data were used to calculate the structure of INSL3. Structures
were calculated by simulated annealing followed by refinement
and energy minimization in a water shell. Ambiguous cross-
peaks were subsequently assigned based on preliminary struc-
tures. Althoughmost amides exchangedwithinminutes a num-
ber were still visible after 1 h. Because these were all found to be
consistent with the hydrogen bond patterns of the elements of
secondary structure in preliminary structures, they were
included as restraints in the calculations.
Description of the Three-dimensional Structure of Human
INSL3—Fig. 2 shows a superimposition of the family of 20
structures representing the solution structure of INSL3. It is
clear that INSL3 adopts a typical relaxin/insulin fold with a well
defined core but with several distorted regions. The structural
statistics (summarized in Table 1) show that the structures are
in good agreement with the experimental data and have favor-
able covalent geometry. The A-chain comprises two parallel
-helical regions (residues A5–A12 and A17–A24) separated
by an extended segment (residues A14–A16). The latter forms
a small -sheet by hydrogen bonding to the B-chain segment
B6–B8. The B-chain contains a longer helical segment, which
spans residues B12–B22 and is oriented across the face of the
two A-chain helices. The fold is cross-braced by the A10–A15,
A11–B10, and A24–B22 disulfide bonds, which hold the pep-
FIGURE 2. Upper: stereo view of superimposition of the peptide backbone of the 20 lowest energy structures representing the solution structure of human
INSL3. For clarity the well defined regions, which include residues A5–A24 and B6–B22, are shown in blackwith the disordered termini in gray. Lower: ribbon
diagram of human INSL3 (left) and schematic showing broadened regions of INSL3 in gray (right).
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tide chains together around a hydrophobic core comprising the
side chains of ProA6, CysA10, CysA15, LeuA20, LeuA23, CysA24,
LeuB9, CysB10, PheB14, IleB15, AlaB17, LeuB18, and CysB22. As
evident from the overlay of the family of INSL3 structures, both
N termini (A1–A4 and B1–B5) are disordered and appear to be
flexible in solution, consistent with a lack of medium and long
range NOEs as well as chemical shifts close to random coil
values. The orientations of the C-terminal tails of both chains,
which extend away from the helical segments, are also poorly
defined. Interestingly, although in the B-chain C-terminal tail
there are few NOEs associated with the peptide backbone and
only small deviations from random coil chemical shifts, a num-
ber of NOEs can be seen between the TrpB27 side chain and
LeuB18, ValB19, and the CysA24–CysB22 disulfide bond, suggest-
ing that the tail can wrap around and interact with this part of
the molecule. We recently reported such an interaction for H3
relaxin, but in that case the tail appeared to have a well defined
conformation. In INSL3 these interactions appear to be tran-
sient, with the Trp and the rest of the tail being mobile in solu-
tion. Further evidence for this proposal is the presence of a
minor conformation observed for TyrA26 whose aromatic side
chain displays similar NOEs to LeuB18 and ValB19. This interac-
tionwould not be possible if the Trp B27 side chain permanently
interacted with and thus prevented the interaction of LeuB18
and ValB19 with other residues.
Effects of B-chainAlanine Substitutions on LGR8Binding and
Activation—Alanine substituted INSL3 analogs were tested for
their ability to compete with 125I-INSL3 binding to HEK-293T
cells stably transfected with LGR8. Additionally, selected
INSL3 analogs were tested for their ability to stimulate cAMP
accumulation in LGR8-transfected cells. INSL3 bound to LGR8
with high affinity (pKi 9.34 0.02) and activated cAMPaccu-
mulation with high efficacy (pEC50 10.24 0.12) (Table 2) in
a similar manner to that previously described (12, 15). INSL3
analogs with single Ala substitutions at HisB12, HisB13, or
ArgB20 did not change LGR8 binding affinity. In contrast, ana-
logs with single Ala substitutions at either ArgB16 (pKi 8.49
0.09; p  0.001) or ValB19 (pKi  8.36  0.11; p  0.001) did
exhibit decreased binding affinity relative to INSL3 (Fig. 3 and
Table 2). Interestingly, analogs with pairs of Ala substitutions
(HisB12 plus ArgB16, pKi  7.81  0.04; ArgB16 plus ArgB20,
pKi  7.82  0.14) resulted in a decreased affinity compared
with the single ArgB16 Ala-substituted analog (p  0.001). An
analogwith threeAla substitutions (HisB12, ArgB16, andArgB20)
resulted in a further decrease in affinity (pKi  7.33  0.07)
(p  0.001) compared with the double Ala-substituted analog
(Fig. 3B and Table 2). Hence, although substitution of either
HisB12 or ArgB20 alone for Ala does not affect LGR8 binding, it
appears that they somehow cooperate with ArgB16 for optimal
binding of INSL3 to LGR8.We also examined a B1–26 truncated
INSL3 analog in our binding assays and found that it exhibited a
dramatically reduced binding affinity (pKi  6.86  0.06) com-
pared with INSL3. This result is consistent with previous data,
which demonstrated that this truncation (leading to a loss of
TrpB27) results in a decrease, but not complete loss, of binding
affinity (13). Importantly themutation of all the proposed binding
residues to create AlaB12/16/19/20/27 INSL3 resulted in a peptide
with nobinding affinity for LGR8. Binding affinitieswere reflected
in efficacies in stimulating cAMP accumulation from LGR8-ex-
pressing cells (Table 2). Hence, the single ArgB16 3 Ala point-
substituted analog demonstrated lower activity than INSL3
(pEC50  8.93  0.15; p  0.001 versus INSL3) and the triple
(HisB12, ArgB16, and ArgB20) Ala-substituted analog resulted in a
further decrease in activity (pEC50 8.06 0.17; p 0.001 versus
INSL3; p 0.05 versusArgB163Ala) (Fig. 3C).
DISCUSSION
Given its importance in the control of testis descent and
modulation of germ cell function, the precise molecular mech-
TABLE 1
NMR and refinement statistics for the NMR structure of INSL3
NMR distance & dihedral constraints
Distance constraints
Total inter-residue NOE 430
Sequential (i j 1) 200
Medium range (i j 4) 140
Long range (i  j  5) 90
Hydrogen bonds 28 (for 14 H-bonds)
Total dihedral angle restraints
phi 16
chi-1 11
Structure statistics
Violations
Distance constraints (0.3 Å) 0.3 0.6
Dihedral angle constraints (3°) 0
Maximum distance constraint violation (Å) 0.33
Maximum dihedral angle constraint violation (°) 2.9
Deviations from idealized geometry
Bond lengths (Å) 0.00412 0.00022
Bond angles (°) 0.66 0.18
Impropers (°) 0.49 0.03
Average pairwise root mean square deviationa (Å)
Heavy 0.66 0.18
Backbone 1.51 0.26
Ramachandran statistics
Most favored regions 74.2% (89%)b
Additionally allowed 22% (10.8%)
Generously allowed 3.7% (0.2%)
Disallowed 0.1% (0%)
a Pairwise root mean square deviation was calculated among 20 refined structures
over residues A6–24 and B6–B22.
bOnly the structurally ordered regions A5–A24 and B6–B22 are reported in
parentheses.
TABLE 2
Binding affinities (pKi: n 3–5) and efficacy in stimulating cAMP
accumulation (pEC50: n 3) of INSL3 analogs in LGR8-expressing
cells
Analog
125I-INSL3 binding cAMPaccumulation
pKi n pEC50 n
INSL3 9.34 0.02 4 10.24 0.12 3
HisB123 Ala INSL3 9.23 0.05 3
HisB133 Ala INSL3 9.73 0.20a 3
ArgB163 Ala INSL3 8.49 0.09b 4 8.93 0.15b 3
ValB193 Ala INSL3 8.36 0.11b 5
ArgB203 Ala INSL3 9.28 0.05 5
AlaB12/16 INSL3 7.82 0.14b,c,d 3
AlaB16/20 INSL3 7.81 0.04b,c,d 3
AlaB12/16/20 INSL3 7.33 0.07b,e 4 8.06 0.17b,e 3
AlaB12/16/19/20/27 INSL3 No binding
B1–26 INSL3 6.86 0.06b 3
a p 0.05 compared to INSL3.
b p 0.001 compared to INSL3 (analysis of variance and Bonferroni multiple com-
parison test).
c p 0.001 compared to ArgB163 Ala INSL3.
d p 0.001 compared to AlaB12/16/20 INSL3.
e p 0.05 compared to ArgB163 Ala INSL3.
Solution Structure of INSL3
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anism of the interaction of INSL3 with its receptor is of consid-
erable interest. Using the structural information acquired for
INSL3, together with an alignment of evolutionarily conserved
residues, we have been able to postulate the LGR8 binding res-
idues of the INSL3 peptide and have subsequently synthesized a
series of Ala-substituted B-chain analogs and examined their
ability to bind to and activate the INSL3 receptor LGR8.
The Solution Structure of Human INSL3 and Comparison to
the Structures of H3 and H2 Relaxin—Fig. 4 shows a compari-
son of the structures of INSL3, H3 relaxin (18), and H2 relaxin
(23) from which it is clear that the peptides have a very similar
core, with the key differences being mainly around the termini.
In both H2 and H3 relaxin the A-chains are highly structured.
In contrast, in INSL3 residues A1–4 are disordered, with the
first structurally ordered residue beingAsnA5, as evident from a
number of medium range helical-type NOEs, in particular to
ArgA8. In both H2 and H3 relaxins the A-chains finish with a
C-terminal cysteine residue that, due to the covalent link to its
disulfide bond partner, locks the chain into its helical confor-
mation. Although the INSL3 A-chain has a similar helical con-
formation, it contains two additional C-terminal residues,
ProA25 and TyrA26, which are structurally disordered in the
main conformer of INSL3. However, there are also peaks in the
spectra originating from a minor conformation of TyrA26. This
conformation displays NOE contacts to a minor conformation
of LeuB18, confirming that in some conformations TyrA26 inter-
acts with the rest of the molecule. This interaction is also con-
sistent with the methyl signals of the minor conformation of
LeuB18 being shifted upfield by ring-current effects from
TyrA26. It is possible that this conformation involves a cis pep-
tide bond preceding ProA25, but this could not be confirmed
due to resonance overlap.
The B-chain N terminus appears to be flexible and lacks a
preferred orientation in both INSL3 and H3 relaxin. Of more
interest is the conformation of the longer C-terminal tail. In the
crystal structure of H2 relaxin the C-terminal helix extends one
turn further than in H3 relaxin and INSL3. However the tail
following the helix, including the conserved Trp, is flexible and
lacks significant electron density in the crystal structure. In
contrast, in H3 relaxin we observed a large number of NOEs
between the Trp side chain and resonances in the molecular
core, including B18, B19, and the A24–B22 disulfide bond (18).
These NOEs were enough to define a conformation in which
the tail turns around and the Trp side chain packs against the
core and forms favorable hydrophobic interactions. Interest-
ingly similar NOEs are observed for INSL3, although in this
case the tail does not seem to have a well defined position,
raising the possibility that the tails in all relaxins are flexible to
differing degrees. Given the involvement of residues in the tail
and the B-chain helix in receptor binding and biological activ-
ity, this flexibility may be important for the selectivity of the
peptides for their respective G-protein-coupled receptors.
Aside from the flexible terminal regions, the presence of
broad resonances for a number of other residues in INSL3
reflects internal dynamical processes in themolecular core.We
recently reported similar broadening for certain resonances in
H3 relaxin (18). Interestingly, the same residues are broadened
in both peptides, although to a more severe degree in INSL3,
with several amide protons being undetectable. The broaden-
ing appears to be mainly centered around the CysA10–CysA15
disulfide bond, making it likely that dynamic flipping of the
disulfide bond conformation is the primary cause of the broad-
ening. Evidence for dynamic processes in the formof resonance
broadening andminor conformations such as is described here
is not unusual in solution-state NMR and reflects the dynamic
nature of protein structures.
Structure-Activity Relationships of INSL3—Recent studies
have revealed that the INSL3 B-chain residues 11–27 are
needed for binding to the LGR8, with TrpB27, which we now
know from the current study lies in the B-chain tail beyond the
helix, playing a crucial role (13). However, the key residues in
the binding of H2 relaxin to LGR7 are correlated to a
RXXXRXXI motif within the B-chain helix (24). Thus it was
likely that the binding of INSL3 to LGR8 also relied on addi-
tional residues in its B-chain helix. The residues at equivalent
positions in INSL3 are HisB12, ArgB16, and ValB19, and thus
FIGURE 3. A and B, competition binding studies of human INSL3 and Ala-
substituted INSL3 analogs in HEK-293T cells stably transfected with LGR8
using 125I-INSL3 as the radioligand. Data are expressed as % specific binding
and are pooled data from three experiments performed in triplicate. C,
ligand-stimulated cAMP accumulation in LGR8-expressing cells measured
using a pCRE--galactosidase reporter gene system. Data are expressed as
percent maximum INSL3 response and are pooled data from three experi-
ments performed in triplicate.
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these were considered primary candidates for further determi-
nants of INSL3 bioactivity. In the solution structure presented
here, the side chains of these residues are indeed presented on
one side of the B-chain helix. Fig. 5 shows a comparison of the
active sites of INLS3, H2 relaxin, and H3 relaxin and illustrates
the projections of the different side chains. In addition to the
residues equivalent to the relaxin tri-peptide binding motif,
other residues in this region of INSL3 were found to have a
significant degree of surface exposure, including HisB13 and
ArgB20, and these therefore might also be in a position to influ-
ence receptor binding. Based on this observation our alanine
substitution strategy also involved these residues. Strikingly, of
the single Ala substituted analogs, only ArgB16 3 Ala and
ValB19 3 Ala showed significantly reduced affinity for LGR8.
FIGURE 4. Comparison of solution structure of human INSL3 (A), solution structure of H3 relaxin (PDB code 2FHW (18) (B), and crystal structure of H2
relaxin (PDB code 6RLX (23) (C).All structures are shown as ribbon diagramswith the disulfides in ball-and-stick representation. The figurewas generated in
MOLMOL (28).
FIGURE 5.Comparisonof theputative primary receptor binding regionof human INSL3 (A), H3 (B), andH2 (C) relaxin. The positioning of the side chains
of the residues known to be crucial for activity in INSL3 and H2 relaxin are shown in stick representation. It is important to note that, although the projections
of these side chains can be predicted from the structures, their exact conformations when bound to the receptor are not known. In the NMR structures these
residues are free in solution anddisorderedwhile in the crystal structure of H2 relaxin bothArgB12 (R12) andArgB16 (R16) are involved in salt bridge interactions
across the crystallographic dimer interface and thus likely adopt a conformation different from the active monomer.
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However, in multi-Ala-substituted analogs, the absence of
either HisB12 or ArgB20 had a strong synergistic effect in com-
bination with ArgB16. This suggests that HisB12 and ArgB20 may
form additional interactions with the receptor or at the very
least assist in the initial recognition step that is most likely gov-
erned by long-range electrostatic interactions between the
basic residues of the hormone and acidic residues on the
receptor.
For completeness, an analog of INSL3, lacking the C-termi-
nal tail, including TrpB27, that has decreased activity (13) was
synthesized and analyzed. This (des-B27–31)-INSL3 analog
demonstrated a similarly reduced affinity for LGR8 as the
HisB12-, ArgB16-, and ArgB20-substituted INSL3 peptide.
Importantly, the combined mutation of TrpB27 together with
HisB12, ArgB16, ValB19, and ArgB20 to Ala resulted in a peptide
with no binding affinity for LGR8, highlighting the fact that all
of these residues are required for high affinity binding. All of the
Ala-substituted analogs were analyzed by circular dichroism
spectroscopy and found to possess either insignificant or very
small secondary structural changes relative to the native human
INSL3.5 NMR analysis of a representative set of Ala mutants,
including those with one, two, three, and five substitutions,
showed that they uniformly had well dispersed spectra (supple-
mentary data) consistent with well folded conformations. Thus
the substitutions did not introduce perturbations to the overall
structure that might have altered the activity through second-
ary conformational effects.
Interestingly the positioning of TrpB27 in the current struc-
ture remains uncertain. Most of the B23-B31 tail of INSL3 has
chemical shifts differing very little from random coil. Further-
more, apart from the TrpB27 NOEs to LeuB18 and ValB19, no
non-sequential NOEs are seen in this region, strongly suggest-
ing a dynamic tail without a preferred orientation. It is therefore
likely that the tail does not adopt its active conformation until it
binds to the receptor. Fig. 6 shows the INSL3 receptor binding
surface both with the tail in the conformation suggested by the
NOEs to the INSL3 core and with the tail removed. In the latter
case a continuous primary binding interface is formed in which
HisB12, ArgB16, ValB19, and ArgB20 are all fully exposed. As a
substantial part of this surface is covered by the tail, as shown in
Fig. 5A, it is likely that the tail moves away from this position
upon binding and interacts with the receptor at a position that
may be either distant from or within close proximity to the
B-chain surface, depending on whether the tail extends out or
coils up. In a recent report, INSL3 analogs with chemical
restraints introduced between the A-chain C terminus and
position B26were synthesized to keepTrpB27 in a fixed position
relative to the terminal region (25). Analogs with linkers that
were too short had significantly reduced activity, whereas those
analogs where the linker maintained the distance between the
-carbons of A26 and B26 to 10–11 Å were highly active (25).
This strongly supports the concept of a more extended confor-
mation in the B-chain tail in which the TrpB27 interacts with
LGR8 in a region separate to that of the B-chain helix binding
site. It is interesting to note that, even though INSL3 has similar
residues to those of the H2 relaxin receptor binding tripeptide
motif (HisB12, ArgB16, and ValB19), INSL3 has a very poor affin-
5 K. J. Rosengren, S. Zhang, F. Lin, N. L. Daly, D. J. Scott, R. A. Hughes, R. A. D.
Bathgate, D. J. Craik, and J. D. Wade, unpublished data.
FIGURE 6. The receptor binding surface of human INSL3. A, surface of the lowest energy structure of INSL3 with the residues determining binding activity
indicated. As seen here parts of the important residues HisB12 (pink), ArgB16 (red), ValB19 (red), and ArgB20 (pink) are covered by the C-terminal tail, including the
crucial TrpB27 (green). B, viewof the same surface of the B-chain helixwith theC-terminal B23–B31 residues removed. This picture represents a possible binding
surface if in the active conformation TrpB27 moves away from themolecule and interacts with the receptor at a point separate from the B-chain helix binding
site.
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ity for the relaxin receptor LGR7. A possible reason for this is
the presence of an Arg (in INSL3) instead of an Ala (in H2
relaxin) at position B20. Although we have shown that the Arg
can assist in coordinating the interaction with LGR8, its posi-
tive charge and considerable bulkiness relative to Ala may be
unfavorable for interacting with the H2 relaxin receptor LGR7.
The flexibility of the N-terminal A-chain helix of INSL3 is
interesting in the light of a recent result showing that, although
a truncated analog lacking the first six amino acids retains full
activity, a second analog in which residues A1–A8 have been
removed is a potent antagonist of INSL3 at LGR8 (26). These
results indicate that, although the regions important for the
primary binding to the receptor are located in the B-chain, a
secondary interaction involving the A-chain is needed to acti-
vate the receptor signal. Here we have shown that residues
A1–A4 are unstructured in solution, consistent with their lack
of functional roles, whereas residues A5–A11 adopt the helical
conformation that is typical for the relaxin/insulin-like fold.
The dynamic character of this helix is crucial for the function of
insulin (27) and may also be needed for INSL3 activity.
Based on the results presented here a mechanism for LGR8
activation by INSL3 may be proposed. This model involves an
initial, primarily electrostatic interaction involving residues
HisB12, ArgB16, and ArgB20, followed by a repositioning of the
B-chain tail and the hormone “locking in” to the correct posi-
tion by anchoring the crucial TrpB27 residue. A second recog-
nition event would follow inwhich parts of theA-chain interact
with a second site on LGR8 to induce a conformational change
allowing the generation of signaling events.
In summary, we have used NMR techniques to solve the
structure of human INSL3 in solution, and through analysis of a
series of synthetic Ala-substituted analogs, used the structure
to help propose a molecular mechanism for the binding of
INSL3 to its receptor, LGR8. A thorough understanding of the
features controlling the biological activities of relaxin family
peptides will be of importance for the future design of antago-
nists/agonists for use as pharmacological probes as well as for
pharmaceutical applications.
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Figure 1.  Series of 1D NMR spectra of INSL3 at selected pH values in the range 2.7 to 
7.4. The spectra highlight the fact that there is increased broadening of peaks at higher 
pH values, but that in general the spectral dispersion remains unchanged, suggesting no 
substantial pH-induced conformational changes. The broadening results in loss of a 
number of signals in 2D spectra at higher pH values, making it preferable for the 
structural analysis to be undertaken at approximately pH 4. 
 
Figure 2.  Series of 1D NMR spectra of selected one, two, three and five-residue Ala 
substituted mutants of INSL3. The excellent dispersion confirms that the mutants are well 
structured and combined with analysis of TOCSY spectra of selected mutants it is clear 
that there do not appear to be conformational changes associated with the mutations. 
 
 
 
INSL analog MH+ (theory) MH+ 
(found) 
HisB12→Ala 6226.30 6227.44 
HisB13→Ala 6226.30 6226.80 
ArgB16→Ala 6207.26 6208.88 
ValB19→Ala  6264.30 6265.84 
ArgB20→Ala 6207.26 6208.99 
B12,16→Ala 6141.19 6141.65 
B16,20→Ala 6122.15 6123.78 
B12,16,20→Ala   6056.08 6057.76 
B12,16,19,20,27→Ala   5912.87 5911.63 
B1-26 5717.79 5717.84 
hINSL3 6292.37 6291.99 
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